<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617821</url>
  </required_header>
  <id_info>
    <org_study_id>CSPAC-28</org_study_id>
    <nct_id>NCT04617821</nct_id>
  </id_info>
  <brief_title>AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>A Phase Ⅲ, Randomized Controlled Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine Versus mFOLFIRINOX in Treating Patients With Borderline Reseactable and Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, randomized, controlled phase Ⅲ study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three hundred patients with borderline resectable and locally advanced pancreatic cancer will&#xD;
      be randomized 1:1 (150 :150) to the AG and mFOLFIRINOX chemotherapy groups and to observe the&#xD;
      overall survival.&#xD;
&#xD;
      The AG regimen: albumin-bound paclitaxel and gemcitabine are given intravenous infusion,&#xD;
      repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycles.&#xD;
&#xD;
      MFOLFIRINOX: Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium&#xD;
      formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30&#xD;
      minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued&#xD;
      for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.&#xD;
&#xD;
      After neoadjuvant chemotherapy, the surgery will be evaluated according to the patient's&#xD;
      tumor and systemic condition.&#xD;
&#xD;
      The first cycle of adjuvant chemotherapy begins 4-8 weeks after radical resection, and the&#xD;
      choice of adjuvant chemotherapy regimen depends on the response to neoadjuvant&#xD;
      chemotherapy.If neoadjuvant chemotherapy is effective, adjuvant chemotherapy maintains the&#xD;
      original regimen.Adjuvant chemotherapy has 4 cycles of treatment.&#xD;
&#xD;
      Relevant examinations were performed before and after each cycle of medication to assess&#xD;
      safety events, imaging review was performed every 2 cycles during the treatment period and&#xD;
      every 3 months during the follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three hundred patients with borderline resectable and locally advanced pancreatic cancer are randomized 1:1 to the AG and mFOLFIRINOX chemotherapy groups and to observe the total survival.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>from randomization to death, up to 36 months</time_frame>
    <description>To evaluate the overall survival of patients with borderline resectable and locally advanced pancreatic cancer after treated neoadjuvant chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence free survival</measure>
    <time_frame>from randomization to recurrence, up to 36 months</time_frame>
    <description>To evaluate the recurrence free survival of patients with borderline resectable and locally advanced pancreatic cancer after treated neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 36 months</time_frame>
    <description>To evaluate the objective response rate of patients with borderline resectable and locally advanced pancreatic cancer after treated neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resection rate</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The proportion of patients who become operable from inoperable after neoadjuvant chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The proportion of R0 resection among patients who undergo operations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The incidence of postoperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Borderline Resectable Pancreatic Cancer</condition>
  <condition>Locally Advanced Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>albumin bound paclitaxel plus gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albumin-bound paclitaxel and gemcitabine were given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOFLIRINOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel plus gemcitabine</intervention_name>
    <description>Albumin-bound paclitaxel and gemcitabine are given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycle.</description>
    <arm_group_label>albumin bound paclitaxel plus gemcitabine</arm_group_label>
    <other_name>AG regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFIRINOX</intervention_name>
    <description>Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.</description>
    <arm_group_label>mFOFLIRINOX</arm_group_label>
    <other_name>modified FOLFIRINOX regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed content obtained prior to treatment&#xD;
&#xD;
          -  Age ≥18 years and ≤ 80 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤1&#xD;
&#xD;
          -  Radiographically confirmed after borderline resectable or locally advanced pancreatic&#xD;
             adenocarcinoma.&#xD;
&#xD;
          -  No any other anti-tumor therapy prior to neoadjuvant chemotherapy, including&#xD;
             intervention chemoembolization, ablation, radiotherapy, chemotherapy and molecular&#xD;
             targeted therapy.&#xD;
&#xD;
          -  No any other anti-tumor therapy prior to neoadjuvant chemotherapy, including&#xD;
             intervention chemoembolization, ablation, radiotherapy, chemotherapy and molecular&#xD;
             targeted therapy.&#xD;
&#xD;
          -  No serious blood system, heart, lung function abnormalities and immune defects (refer&#xD;
             to the respective standards)&#xD;
&#xD;
          -  White blood cell (WBC) ≥ 3 × 109/L; Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;&#xD;
             Platelets (PLT) ≥ 100 × 109/L; Hemoglobin (Hgb)≥ 9 g/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT]/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) ≤&#xD;
             2.5 × institutional upper limit of normal (ULN); Total bilirubin (TBIL) ≤ ULN;&#xD;
             Creatinine (CRE) ≤ 1.5 × ULN&#xD;
&#xD;
          -  Prothrombin time (PT) and international normalized ratio (INR) ≤ 1.5 ×ULN&#xD;
&#xD;
          -  Comply with research visit plans and other program requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with other systemic malignancies&#xD;
&#xD;
          -  Patients who were treated with any other anti-tumor therapy prior to neoadjuvant&#xD;
             chemotherapy, including intervention chemoembolization, ablation, radiotherapy,&#xD;
             chemotherapy and molecular targeted therapy.&#xD;
&#xD;
          -  used any other study drug within 7 days prior to enrollment;&#xD;
&#xD;
          -  Patients with central nervous system diseases, mental illness, unstable angina&#xD;
             pectoris, congestive heart failure, severe arrhythmia and other serious diseases that&#xD;
             cannot be controlled&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to study drug and alike.&#xD;
&#xD;
          -  Patients who are using and expected to use warfarin in long term&#xD;
&#xD;
          -  Patients may leave the observation for 14 days or more during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xian-Jun Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xian-Jun Yu, MD, PhD</last_name>
    <phone>+86 21 64175590</phone>
    <email>yuxianjun@fudanpci.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen-Quan Wang, MD, PhD</last_name>
    <phone>+86 21 64175590</phone>
    <email>wangwenquan@fudanpci.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XianJun Yu, M.D., Ph.D.</last_name>
      <phone>+86-21-6417-5590</phone>
      <email>yuxianjun@fudanpci.org</email>
    </contact>
    <investigator>
      <last_name>Xianjun Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xian-Jun Yu</investigator_full_name>
    <investigator_title>Vice President of Fudan University Shanghai Cancer Center</investigator_title>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>albumin bound paclitaxel</keyword>
  <keyword>mFOLFIRINOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

